Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
N
Nader, Ahmed
Clinical Pharmacology, Modelling and Simulation, GSK
PII-020
-
SIMILAR BIOAVAILABILITY OF SUBCUTANEOUS BEPIROVIRSEN WHEN DELIVERED FROM A VIAL OR PREFILLED SYRINGE FITTED WITH A SAFETY SYRINGE DEVICE IN HEALTHY ADULT PARTICIPANTS
Ahmed Nader
Favorite
Naderer, Odin
Chimerix, Inc.
PI-040
-
THE EFFECT OF DORDAVIPRONE (ONC201) ON CARDIAC REPOLARIZATION IN HEALTHY ADULT PARTICIPANTS
Odin Naderer
Favorite
Nahid, Noor
Ohio State University
PII-043
-
ASSOCIATION BETWEEN CYP2D6 GENOTYPE-INHIBITOR INTERACTIONS AND PAIN-RELATED EMERGENCY DEPARTMENT VISITS IN CYP2D6-OPIOID-TREATED PATIENTS
Noor Nahid
Favorite
Nakhla, Keroles
BMS
PI-026
-
A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS
Keroles Nakhla
Favorite
PII-110
-
AN OVERVIEW OF FOOD EFFECT STUDIES IN PEDIATRIC POPULATION SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) (2004-2024)
Keroles Nakhla
Favorite
Natesan, Divya
University of Pittsburgh, School of Medicine
PI-034
-
ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK
Divya Natesan
Favorite
Nayak, Satyaprakash
Pfizer Inc.
PII-106
-
POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Satyaprakash Nayak
Favorite
Neal, Reem
UT Southwestern Medical Center
PI-007
-
PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.
Reem Neal
Favorite
Neuhoff, Sibylle
Certara UK
LB-018
-
BUILDING AN OAT-MATRIX: PERFORMANCE VERIFICATION OF IVIVE-PBPK MODELS IN THE PREDICTION OF OAT1/OAT3 MEDIATED DRUG-DRUG INTERACTIONS
Sibylle Neuhoff
Favorite
PII-002
-
APPLICATIONS AND LIMITATIONS OF 4ΒETA-HYDROXYCHOLESTEROL AS A SENSITIVE ENDOGENOUS BIOMARKER
Sibylle Neuhoff
Favorite
Ngara, Bernard
University of California San Francisco
PI-061
-
CLOFAZIMINE PHARMACOKINETICS FOR MULTIDRUG-RESISTANT TB: IMPLICATION OF NOVEL COMBINATION REGIMENS.
Bernard Ngara
Favorite
PII-093
-
TRANSLATIONAL MODELING OF BTZ-043 IN PREDICTING PHASE IIA EFFICACY AND EVALUATION OF DRUG-DRUG INTERACTIONS WITH BPAL IN MURINE MODELS
Bernard Ngara
Favorite
Nguyen, Chi Huu
X4 Pharmaceuticals (Austria) GmbH, Vienna, Austria
E-006
-
CXCR4 ANTAGONISM CORRECTS PERIPHERAL NEUTROPENIA IN A MOUSE MODEL OF WHIM SYNDROME.
Chi Huu Nguyen
Favorite
Nguyen, Duyen
U.S. Food and Drug Administration
PI-109
-
IMPACT OF RISK EVALUATION AND MITIGATION STRATEGY PROGRAMS ON PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT
Duyen Nguyen
Favorite
Nguyen, Thomas
University at Buffalo, School of Pharmacy & Pharmaceutical Sciences, Division of Clinical & Translational Therapeutics
PII-021
-
VIRAL VANGUARD: TURNING THE TIDE AGAINST SUPERBUGS
Thomas Nguyen
Favorite
Nishii, Rina
Bristol Myers Squibb
PII-004
-
EVALUATING THE UTILITY OF ENDOGENOUS OCT2 AND MATE1/2-K BIOMARKERS FOR EARLY DDI ASSESSMENT IN ONCOLOGY PHASE 1 STUDIES
Rina Nishii
Favorite
Nittu, Satyavardhan Rao
University of Florida
PII-046
-
GENETIC VARIANTS PREDICTIVE OF FEBRILE NEUTROPENIA DURING INDUCTION I IN PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS
Satyavardhan Rao Nittu
Favorite
Norris, Madeline
University of Florida
PI-042
-
AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.
Madeline Norris
Favorite
TIP-002
-
EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.
Madeline Norris
Favorite